Recent Advances in Liver Cirrhosis
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 2764
Special Issue Editor
Special Issue Information
Dear Colleagues,
Liver cirrhosis is a progressive and dynamic chronic liver disease. It is widely prevalent worldwide and can be caused by different causes, such as chronic viral hepatitis, alcohol-associated liver disease, metabolic-associated fatty liver disease/nonalcoholic fatty liver disease (MAFLD/NAFLD) and so on. The major complications of cirrhosis include varices, ascites, hepatic encephalopathy (HE), hepatopulmonary hypertension, hepatocellular carcinoma, hepatorenal syndrome, spontaneous bacterial peritonitis, and coagulation disorders.
The pathogenesis of cirrhosis and its complications is very complex; this is because early diagnosis is often difficult, and the disease usually goes unnoticed for a long time. The pharmacological community has paid very limited attention to the early stages of cirrhosis, resulting in few current drugs targeting liver cirrhosis. Moreover, comorbidities of cirrhosis were ruled out for most of the new drugs.
Therefore, we are excited to inform you of our Special Edition titled “Recent Advances in Liver Cirrhosis” for the journal Biomedicines. We welcome submissions with a focus on the disease burden, pathophysiology, early diagnosis, and monitoring of cirrhosis, and the novelty therapeutic strategies of its complications.
Dr. Andrzej Prystupa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- liver cirrhosis
- liver fibrosis
- portal hypertension
- cholestatic liver disease
- liver failure
- hepatocellular carcinoma
- non-alcoholic steatohepatitis
- variceal bleeding
